GREENWOOD VILLAGE, Colo.,
Aug. 3 /PRNewswire-FirstCall/ --
Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE), discovered
an error in the title of its press release on July 27, and provides the corrected title to that
release above. As reflected in the body of the press release, Ampio
has completed the final negotiations with DMI BioSciences, Inc.
concerning the pending acquisition of DMI BioSciences. Ampio will
file a Form 8-K with the SEC announcing the definitive agreement
upon its execution.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. develops innovative proprietary
drugs for metabolic disease, eye disease, kidney disease,
inflammation and CNS disease. The product pipeline includes new
uses for previously approved drugs and new molecular entities
("NMEs"). By concentrating on development of new uses for
previously approved drugs, approval timelines, costs and risk of
clinical failure are reduced because these drugs have strong
potential to be safe and effective while their shorter development
times can significantly increase near-term value. A key strategy
includes actively exploring partnership, licensing and other
collaboration opportunities to maximize Ampio's product development
programs.
About DMI BioSciences, Inc.
DMI BioSciences, Inc. was founded by Dr. David Bar-Or in 1990 to
develop innovative diagnostic tests and drugs for the medical
device and biopharmaceutical industry.
Safe Harbor Statement
Certain of the above statements contained in this press release
are forward-looking statements that involve a number of risks and
uncertainties. Such forward-looking statements are within the
meaning of that term in Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Readers are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those indicated in the forward-looking statements as a result of
various factors.
Investor Contact: Redwood Consultants, LLC Tel: +1
415-884-0348
SOURCE Ampio Pharmaceuticals, Inc.
Copyright g. 3 PR Newswire